Plain-English translation of NCT04569448 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called as an add-on treatment for bipolar depression. works differently than many existing medications by helping to balance dopamine and serotonin in the brain, which are chemicals involved in mood and motivation. The study wants to see if adding this medication to your current treatment can help reduce depression symptoms that haven't fully responded to other treatments.
People with bipolar disorder spend much of their time in depressive states, and depression often becomes harder to treat over time and with repeated episodes. Because this medication works through a unique mechanism that may help with motivation, energy, and thinking problems—which are common in bipolar depression—there is a need to test whether this treatment can help people whose depression hasn't improved with other options.
You likely qualify if…
You likely don't qualify if…
In this study, you would continue taking your current mood stabilizer medication and add the new medication as directed by the research team. Your dose may be adjusted over time based on how you respond and tolerate the treatment. You would attend regular visits to the clinic where the research team would check your symptoms, mood, and overall health through rating scales and possibly laboratory tests.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Canada